What does GENEREX, DOCTEUR ANDRE DELFORGE do?

GENEREX, DOCTEUR ANDRE DELFORGE is a healthcare practice in Vielsalm. Private Limited, started on 5 March 2002.

What is the address of GENEREX, DOCTEUR ANDRE DELFORGE?

The registered office of GENEREX, DOCTEUR ANDRE DELFORGE is located at Rue Eysden-Mines,Gd-Halleux 39, 6698 Vielsalm.

Is GENEREX, DOCTEUR ANDRE DELFORGE still active?

Yes. According to the CBE (17 September 2026) GENEREX, DOCTEUR ANDRE DELFORGE is active, legal situation “Normale toestand”, started on 5 March 2002.

Is GENEREX, DOCTEUR ANDRE DELFORGE registered on Peppol?

Yes, GENEREX, DOCTEUR ANDRE DELFORGE is registered on the Peppol network with ID 0208:0477025511.

What is the enterprise number of GENEREX, DOCTEUR ANDRE DELFORGE?

The enterprise number of GENEREX, DOCTEUR ANDRE DELFORGE is BE0477025511.

When was GENEREX, DOCTEUR ANDRE DELFORGE founded?

GENEREX, DOCTEUR ANDRE DELFORGE was founded on 5 March 2002.

Who are the directors of GENEREX, DOCTEUR ANDRE DELFORGE?

According to the 2024 annual accounts, the directors of GENEREX, DOCTEUR ANDRE DELFORGE are: André Delforge.

Is GENEREX, DOCTEUR ANDRE DELFORGE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 March 2002; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did GENEREX, DOCTEUR ANDRE DELFORGE make in 2024?

GENEREX, DOCTEUR ANDRE DELFORGE posted a profit after taxes of € 157,339 in financial year 2024.

What is the revenue of GENEREX, DOCTEUR ANDRE DELFORGE?

As a small company, GENEREX, DOCTEUR ANDRE DELFORGE is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 237,190.

GENEREX, DOCTEUR ANDRE DELFORGE (Private Limited)

Dossier GENEREX, DOCTEUR ANDRE DELFORGE, printed on 17 September 2026 from databakkes.be/en/0477025511/generex-docteur-andre-delforge. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

GENEREX, DOCTEUR ANDRE DELFORGE from Vielsalm, company number BE0477025511, closed financial year 2024 with a result of € 157,339 after tax. For that financial year GENEREX, DOCTEUR ANDRE DELFORGE recorded a gross margin of € 237,190 and equity of € 1.4 million. Compared with financial year 2023, the result moved from € 139,176 to € 157,339. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2025.

What it is worth Growing

€ 1.4 million

▲ 13% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 157,339

▲ 13% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 136,073

▼ 41% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 1.4 million.

People and assets in 2024

Vehicles and equipment

€ 60,038

▼ 22% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 6,350

▼ 25% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 31,742

▲ 17% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 229,497 Gross margin 2021: € 229,497 First fiscal year in the series	€ 237,268 Gross margin 2022: € 237,268 ▲ 3% vs 2021 (€ 229,497) Favourable step	€ 230,726 Gross margin 2023: € 230,726 ▼ 3% vs 2022 (€ 237,268) Unfavourable step	€ 237,190 Gross margin 2024: € 237,190 ▲ 3% vs 2023 (€ 230,726) Favourable step	▲ 3%
Profit after taxes	€ 140,326 Profit after taxes 2021: € 140,326 First fiscal year in the series	€ 153,069 Profit after taxes 2022: € 153,069 ▲ 9% vs 2021 (€ 140,326) Favourable step	€ 139,176 Profit after taxes 2023: € 139,176 ▼ 9% vs 2022 (€ 153,069) Unfavourable step	€ 157,339 Profit after taxes 2024: € 157,339 ▲ 13% vs 2023 (€ 139,176) Favourable step	▲ 13%
Equity	€ 985,504 Equity 2021: € 985,504 First fiscal year in the series	€ 1,118,573 Equity 2022: € 1,118,573 ▲ 14% vs 2021 (€ 985,504) Favourable step	€ 1,227,749 Equity 2023: € 1,227,749 ▲ 10% vs 2022 (€ 1,118,573) Favourable step	€ 1,385,088 Equity 2024: € 1,385,088 ▲ 13% vs 2023 (€ 1,227,749) Favourable step	▲ 13%
Total debts	€ 34,207 Total debts 2021: € 34,207 First fiscal year in the series	€ 100,891 Total debts 2022: € 100,891 ▲ 195% vs 2021 (€ 34,207) Unfavourable step	€ 126,673 Total debts 2023: € 126,673 ▲ 26% vs 2022 (€ 100,891) Unfavourable step	€ 137,744 Total debts 2024: € 137,744 ▲ 9% vs 2023 (€ 126,673) Unfavourable step	▲ 9%
Cash	€ 439,603 Cash 2021: € 439,603 First fiscal year in the series	€ 389,886 Cash 2022: € 389,886 ▼ 11% vs 2021 (€ 439,603) Unfavourable step	€ 230,440 Cash 2023: € 230,440 ▼ 41% vs 2022 (€ 389,886) Unfavourable step	€ 136,073 Cash 2024: € 136,073 ▼ 41% vs 2023 (€ 230,440) Unfavourable step	▼ 41%
Retained profit	€ 973,104 Retained profit 2021: € 973,104 First fiscal year in the series	€ 1,106,173 Retained profit 2022: € 1,106,173 ▲ 14% vs 2021 (€ 973,104) Favourable step	€ 1,215,349 Retained profit 2023: € 1,215,349 ▲ 10% vs 2022 (€ 1,106,173) Favourable step	€ 1,372,688 Retained profit 2024: € 1,372,688 ▲ 13% vs 2023 (€ 1,215,349) Favourable step	▲ 13%
Dividend	€ 0 Dividend 2021: € 0 First fiscal year in the series	€ 20,000 Dividend 2022: € 20,000 Unchanged (€ 0) Unchanged	€ 30,000 Dividend 2023: € 30,000 ▲ 50% vs 2022 (€ 20,000) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 30,000) Unchanged	▼ 100%
Balance sheet total	€ 1,019,711 Balance sheet total 2021: € 1,019,711 First fiscal year in the series	€ 1,219,464 Balance sheet total 2022: € 1,219,464 ▲ 20% vs 2021 (€ 1,019,711) Unchanged	€ 1,354,423 Balance sheet total 2023: € 1,354,423 ▲ 11% vs 2022 (€ 1,219,464) Unchanged	€ 1,522,833 Balance sheet total 2024: € 1,522,833 ▲ 12% vs 2023 (€ 1,354,423) Unchanged	▲ 12%

Key figures of GENEREX, DOCTEUR ANDRE DELFORGE, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to GENEREX, DOCTEUR ANDRE DELFORGE?

What happened at GENEREX, DOCTEUR ANDRE DELFORGE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 21, 2025 New annual accounts for financial year 2024: profit of € 157,339 (▲ 13% vs 2023). filed late Source: NBB ↗
Mar 5, 2002 Start of the company according to the CBE. KBO

In short

From € 140,326 profit in 2021 to € 157,339 profit in 2024.

Paid € 281,739 in corporate taxes since 2021.

Best year ever: 2024, with € 157,339 profit.

Paid out € 50,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at GENEREX, DOCTEUR ANDRE DELFORGE? We notify you, reason included.

Follow GENEREX, DOCTEUR ANDRE DELFORGE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

André Delforge

GENEREX, DOCTEUR ANDRE DELFORGE

Behind GENEREX, DOCTEUR ANDRE DELFORGE is André Delforge.

See the full network in the app

Directors

According to the 2024 annual accounts

André Delforge

Manager

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Eysden-Mines,Gd-Halleux 39

6698 Vielsalm

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0477.025.511

VAT number

BE 0477.025.511

Registered office

Rue Eysden-Mines,Gd-Halleux 39, 6698 Vielsalm

Names & denominations

GENEREX, DOCTEUR ANDRE DELFORGE

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 March 2002

Peppol

Active · Active since 3 Dec 2025

Activities · NACE

Activiteiten van medische beeldvorming en medische laboratoria

Activiteiten van medische laboratoria

Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗

GENEREX, DOCTEUR ANDRE DELFORGE

Financials

What happened to GENEREX, DOCTEUR ANDRE DELFORGE?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions